Tcrx T cell
Phase 1Biologic
Tcrx T cell is one of 3 biologic programs targeting Gastric/Gastroesophageal Junction Cancer. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Gastric/gastroesophageal Junction Cancer
#DrugCompanyPhaseTrials
1Adstiladrin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 2
Tuoyi
CCoherus Oncology, Inc.
Phase 2
Tcrx T cell
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Gastric/Gastroesophageal Junction Cancer1 trial
TCRx_T Cells for Advanced or Recurrent Gastric/Gastroesophageal Junction Cancer After Failure of First Chemotherapy
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT05447234·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tcrx T cell. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details